SLNO - Soleno Therapeutics to Present at Upcoming February Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences:

Guggenheim Healthcare Talks | 6 ^th Annual Biotechnology Conference
Thursday, February 8, 2024, at 2:30 PM Eastern Time

34 ^th Annual Oppenheimer Healthcare Life Sciences Conference
Wednesday, February 14, 2024, at 11:20 AM Eastern Time

Anish Bhatnagar, M.D., Chief Executive Officer, will also be participating in a fireside chat, hosted by Dr. Leland Gershell.

A live audio webcast and replays of the presentations will be available in the Investors section on the Company’s website at www.soleno.life .

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life .

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578